Ordaōs in the News
We are in the news because we’re making huge strides in human-enabled, machine-driven drug design.
- 2/22/2023Ordaōs and FatiAbGen Partner to Optimize Therapeutics for Challenging Oncology Conditions
- 2/1/2023The Generative AI Revolution is Creating The Next Phase Of Autonomous Enterprise
- 12/19/2022Ordaōs Announces a Joint Development Agreement to Create Novel Therapeutics for AML
- 12/15/2022Ordaōs Announces Appointment of Ziwei Liang, PhD to Role of Chief Science Officer
- 10/12/2022Ordaōs and NonExomics Announce Research Collaboration
- 9/21/2022Mini-Proteins Combine Best of Monoclonals and Small-Molecule Drugs
- 9/12/2022Ordaōs/NonExomics Deal Shines Light on Novel Mini-Proteins
- 8/25/2022Ordaōs Raises $5 Million in Seed to Accelerate Drug Design and Discovery
- 4/22/2021Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
Posters
Read abstracts and sign up to download more info
- AACR 2022: Deep Learning Based Protein Therapeutics Design to Treat HER2+ Cancers
- PEGS 2022: Using deep learning to discover functional antibodies for SARS-CoV-2 with picomolar binding affinity
- AET 2022: Using deep learning to discover functional antibodies for SARS-CoV-2 with picomolar binding affinity
